TRA2B

Chr 3AD

transformer 2 beta homolog

Also known as: Htra2-beta, PPP1R156, RAMELN, SFRS10, SRFS10, TRA2-BETA, TRAN2B

This gene encodes a nuclear protein which functions as sequence-specific serine/arginine splicing factor which plays a role in mRNA processing, splicing patterns, and gene expression. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2011]

OMIMResearchGenerating clinical summary…
MultiplemechanismADLOEUF 0.251 OMIM phenotype
Clinical SummaryTRA2B
🧬
Gene-Disease Validity (ClinGen)
syndromic complex neurodevelopmental disorder · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 0.99). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
6 unique Pathogenic / Likely Pathogenic· 22 VUS of 45 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint?
0.25LOEUF
pLI 0.993
Z-score 3.86
OE 0.05 (0.020.25)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?
3.50Z-score
OE missense 0.30 (0.240.37)
60 obs / 198.7 exp
Constrained

Highly missense-constrained (top ~0.1%)

Observed / Expected Ratios?
LoF OE?0.05 (0.020.25)
00.351.4
Missense OE?0.30 (0.240.37)
00.61.4
Synonymous OE?0.99
01.21.6
LoF obs/exp: 1 / 19.3Missense obs/exp: 60 / 198.7Syn Z: 0.04
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
moderateTRA2B-related neurodevelopmental syndromeOTHERAD

This gene — mechanism propensity

DN
0.3196th %ile
GOF
0.3292th %ile
LOF
0.88top 5%

This gene has evidence for multiple mechanisms of pathogenicity (loss-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to loss-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

LOFprediction above median · 50% of P/LP variants are LoF · LOEUF 0.25
DN1 literature citation

Literature Evidence

DNCONCLUSION: Predicted loss-of-function variants clustered in the 5' portion of TRA2B cause a new neurodevelopmental syndrome through an apparently dominant negative disease mechanism involving the use of an alternative translation start site and the overexpression of a shorter, repressive Tra2β pro1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

References

  1. 1.PMID 36549593

ClinVar Variant Classifications

45 submitted variants in ClinVar

Classification Summary

Pathogenic6
VUS22
6
Pathogenic
22
VUS

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
3
2
1
0
6
Likely Pathogenic
0
0
0
0
0
VUS
5
16
1
0
22
Likely Benign
0
0
0
0
0
Benign
0
0
0
0
0
Total8182028

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

41 pathogenic / likely-pathogenic (of 45) ClinVar copy-number / structural variants overlap TRA2B — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

TRA2B · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →